Background/Objectives: This study evaluated the outcomes of early versus late switching from intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy to dexamethasone (DEX) implants in patients with macular edema secondary to central retinal vein occlusion (CRVO). Here, VEGFA is linked to macular retinal edema.